JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in ItalyArticle Published on 2021-08-232022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] adverse event ambient anti-inflammatory drug baseline C-reactive protein clinical Clinical outcome collected compassionate use COVID-19 decrease experience Hospitalized hyperactive inflammatory response increases in Inflammatory response inhibition inhibitor Italy Jak laboratory parameter lymphocyte observation period outcome oxygen support Patient patients patients with COVID-19 Pneumonia positive Program reported ruxolitinib SARS-CoV-2 severe COVID-19 severe pneumonia Significant Support treated with COVID-19 [DOI] 10.3390/jcm10163752 PMC 바로가기 [Article Type] Article
Randomised, controlled, open label, multicentre clinical trial to explore safety and efficacy of hyperbaric oxygen for preventing ICU admission, morbidity and mortality in adult patients with COVID-19COVID-19를 가진 성인 환자의 ICU 입원, 이환율 및 사망률을 방지하기위한 고압 산소의 안전성 및 효능을 탐색하기위한 무작위, 제어, 개방형 라벨, 다중 센터 임상 시험Randomized Controlled Trial Published on 2021-07-052022-08-31 Journal: BMJ Open [Category] Fulltext, SARS, 임상, 진단, 치료제, [키워드] Analysis anti-inflammatory drug approved best blood sample Blood samples case report form Clinical data clinical trial collected COVID-19 criteria defined Dexamethasone dissemination effective Efficacy electronic case report form Ethics EudraCT evaluate FIVE HBO hyperbaric oxygen Hypothesis ICU ICU admission ICU admissions immunology Inconclusive independent Infectious diseases inflammatory reaction Inflammatory response institutional review board intensive & critical care intensive care intensive care unit load massive inflammatory mitigate molecular analyses morbidity morbidity and mortality Mortality multicentre open Open Access open label oxygen parameter parameters Patient patients with COVID-19 peer-reviewed Pneumonitis positive Prevent primary endpoint product randomisation randomised recorded reduce repeated reported resources risk factor Safe Safety Monitoring Board severe COVID-19 shown subject Swedish Swedish Medical Product Agency tested thoracic medicine Treatment treatment for COVID-19 Trial Trial registration Trigger ventilatory support [DOI] 10.1136/bmjopen-2020-046738 PMC 바로가기 [Article Type] Randomized Controlled Trial
Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus InfectionPharmacology Published on 2021-06-292022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] acute respiratory syndrome anti-inflammatory drug anti-SARS-CoV-2 Anti-viral bioactive compounds caused Chinese component Compound coronavirus coronavirus disease COVID-19 COVID-19 infection death dietary supplement Diseases drugs effective effective vaccine Encephalitis example gastroenteritis Health illnesses increase in kidney knowledge lung Medicine morbidity and mortality multiple organ failure natural compounds Naturally outbreak pandemic provided Research Safe SARS-CoV-2 SARS-CoV-2 infected patient SARS-COV-2 infection Spread Symptom the disease therapeutic potential Therapies therapy Traditional transmitted treat Treatment Treatment strategies upper respiratory tract variety viral infections [DOI] 10.3389/fphar.2021.575877 PMC 바로가기 [Article Type] Pharmacology
Comparative Anti-Inflammatory Effects of Salix Cortex Extracts and Acetylsalicylic Acid in SARS-CoV-2 Peptide and LPS-Activated Human In Vitro SystemsSARS-COV-2 펩티드 및 LPS- 활성화 된 인간 시험 관내 시스템에서 살릭 피질 추출물 및 아세틸 살리실산의 비교 항 염증 효과Comparative Study Published on 2021-06-232022-08-31 Journal: International Journal of Molecular Sciences [Category] MERS, SARS, 치료제, [키워드] Salix species Acetylsalicylic acid acetylsalicylic acid (ASA) acid activated Anti-inflammatory anti-inflammatory drug Anti-inflammatory drugs Anti-inflammatory effects anti-inflammatory treatment Cell cells co-culture Comparative compounds cortex COVID-19 patient Culture cytokine Cytokines Effect Efficacy enzyme activity Extract Fever Human human body human PBMC IL-10 IL-1β IL-6 IMPROVE in vitro in vitro data Inflammation Inflammatory ingredient intestinal liver cell LPS-activated mediator metabolism outcome Pain PBMCs peptide peptides PGE PGE2 precursor prostaglandin prostaglandin E2 protein expression retained salicin salicylic acid SARS-CoV-2 SARS-CoV-2 peptide SARS-CoV-2 peptides suppressed suppression System therapy Willow willow bark [DOI] 10.3390/ijms22136766 PMC 바로가기 [Article Type] Comparative Study
Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infectionSARS-COV-2 감염에 대한 잠재적 약물로서 덱사메타손의 용도를 다른 용도를위한 약물 유전전증 고려 사항Review Published on 2021-06-042022-08-31 Journal: Personalized Medicine [Category] MERS, SARS, 신약개발, 유전자 메커니즘, [키워드] Abstract agonist analgesic effect analgesic effects anti-inflammatory drug benefit changes in chronic patients clinically Control Corticosteroid COVID-19 COVID-19 case Critical cure CYP3A5 Dexamethasone drug drug response Effect effort evaluate Factor Genetic genetic factors Genetic variation glucocorticoid Glucocorticoid receptors Health Organization immunomodulatory drugs individual individuals inherent involved metabolism metabolome NR3C1 NR3C2 outcome pathway Patient patients pharmacogenetics pharmacokinetic pharmacokinetics Potential treatment Randomized controlled trials receptors recovery RECOVERY trial reduce mortality Regulatory reported SARS-CoV-2 SARS-COV-2 infection severe COVID-19 patient severe COVID-19 patients therapy Transcriptome United Kingdom Usage World Health Organization [DOI] 10.2217/pme-2020-0183 PMC 바로가기 [Article Type] Review
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort studyArticles Published on 2021-05-072022-10-29 Journal: The Lancet Rheumatology [Category] COVID-19, [키워드] 95% CI Acute kidney injury adjust Admission age anti-inflammatory drug clinical Cohort cohort study Community confounding variables covariate COVID-19 COVID-19 severity Critical care death disease disease severity Effect England enrolled funding group groups health-care hospital Hospital admission hospitalised patient identify in-hospital mortality invasive ventilation ISARIC Logistic regression Medical Research Council men Mortality multicentre no significant difference non-invasive ventilation non-steroidal anti-inflammatory drug NSAID NSAIDS Occurrence outcome outcomes oxygen pandemic Patient patients with COVID-19 Policy populations Primary outcome propensity score matching prospective cohort study required Result rheumatological SARS-COV-2 infection secondary outcome severity severity of COVID-19 suggested supplementary oxygen variables were recorded women [DOI] 10.1016/S2665-9913(21)00104-1 PMC 바로가기 [Article Type] Articles
Network pharmacology approach to decipher signaling pathways associated with target proteins of NSAIDs against COVID-19Article Published on 2021-05-052022-10-04 Journal: Scientific Reports [Category] SARS, 임상, 치료제, [키워드] alleviate analyzed anti-inflammatory agents anti-inflammatory drug approach approved binding affinity Biotechnology Cell Clinical efficacy Computational biology and bioinformatics Coronavirus disease 2019 COVID-19 docking score drug enrichment analysis excessive inflammation exhibited FDA food genetics Health care highest indomethacin inhibition KEGG Kyoto MAPK10 MAPK8 mechanism Medical research Molecular biology molecular docking network network pharmacology NSAID NSAIDS overlapping Pathway enrichment analysis Patient prediction proinflammatory Protein PubChem RAS Rofecoxib RStudio SARS-CoV-2 selected signaling pathway target target protein target proteins the binding affinity tissue Venn diagram was determined were used [DOI] 10.1038/s41598-021-88313-5 PMC 바로가기 [Article Type] Article
In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approachResearch article Published on 2021-05-012022-10-05 Journal: European journal of pharmaceutical sciences : offi [Category] SARS, 신약개발, [키워드] Acute inflammation analyzed anti-inflammatory drug antiviral agent Apoptosis appear approach azosemide bind binding BiP candidate caspase-dependent apoptosis Cell cell surface contribute COVID-19 COVID-19 / SARS-CoV-2 COVID-19 patients disrupt docking domain drug Drug repurposing drugs targeting expressed extrinsic FDA-approved drug functional Grapiprant hepatitis C virus identify Immune cell infected cells Inflammation inhibit Ligand molecular docking NBD Netupitant neutralize performed polypeptide predicted Prevent protease Protein receptor receptor protein Replication SARS-CoV-2 selected Significance susceptible therapeutic target treat Trigger triggering velpatasvir viral replication [DOI] 10.1016/j.ejps.2021.105771 [Article Type] Research article
Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation기계적 환기가 아닌 SARS-Cov-2 감염 환자에서 룩소리티닙의 동정적 사용: 염증 및 환기에 대한 단기 영향Article Published on 2021-05-012022-09-11 Journal: Clinical and translational science [Category] SARS, 신약개발, [키워드] accompany affected Anti-inflammatory anti-inflammatory drug anti-inflammatory effect Antiviral appear approach baseline benefit Biomarkers biomarkers of inflammation C-reactive protein C-reactive protein (CRP Chain Reaction clinical pharmacology clinical response collected compassionate use compassionate-use contribute coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection criteria CRP Cytokines during treatment Dyspnea Effect effective Evidence hyperinflammation Hypothesis immune cells inclusion criteria Infection Inflammation Inflammatory response inhibit interferons interstitial pneumonia invasive ventilation JAK inhibitor jak inhibitors Jak-STAT janus Janus kinase less Lungs management mechanical ventilation mmHg need for oxygen oxygen oxygen saturation oxygen support PaO pathway Patient patients hospitalized patients with SARS-CoV-2 polymerase chain polymerase chain reaction positive present pro-inflammatory pro-inflammatory cytokines prognostic progression provided reduce reduced reduction reinforcement respiratory Respiratory function ruxolitinib SARS-CoV-2 SARS-COV-2 infection Severe acute respiratory syndrome Side effect significantly more STAT Support Symptom systemic inflammation target the disease therapeutic therapeutic agent therapeutic agents Topic Treatment type I interferon type I interferons Ventilation were recorded [DOI] 10.1111/cts.12971 PMC 바로가기 [Article Type] Article
Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapyCOVID-19 및 암 면역 요법에서 공유된 염증 경로 및 치료 전략Article Published on 2021-05-012022-09-12 Journal: Journal for immunotherapy of cancer [Category] SARS, 진단, [키워드] acute respiratory distress adverse event Allogeneic anti-inflammatory drug Anti-inflammatory therapy antibody Antigen approach ARDS benefit Cancer immunotherapy caused Cell cells characterized chimeric circulating cytokines clinical trial Complication coronavirus COVID-19 CRS cytokine disease drug drugs Effect elevated Endothelial dysfunction exaggerated immune response Graft-versus-host disease help Hospitalization immune system Immunotherapy infection with SARS-CoV-2 Inflammation Inflammation mediators Inflammatory inflammatory pathway inhibiting interleukin-6 interstitial involved mechanism monoclonal antibody Mortality pathogenesis of COVID-19 pathway performed preliminary evidence reducing reduction in SARS-COV-2 infection stimulate suppress syndrome systematic review systemic manifestation therapeutic strategy therapy toxicities Toxicity Treatment trials triggered viral infection [DOI] 10.1136/jitc-2021-002392 PMC 바로가기 [Article Type] Article